A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases

Conditions: Primary Immunodeficiency Diseases (PID) Interventions: Biological: TAK-881 Sponsors: Takeda; Takeda Development Center Americas, Inc. Not yet recruiting

https://clinicaltrials.gov/study/NCT06076642

Source: ClinicalTrials.gov - October 11, 2023 Category: Research Source Type: clinical trials

More News: Primary Immunodeficiency Disease | Research | Study